UnicoCell Biomed Co (TPE:6794) Ending Cash Position: NT$46.55 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6794 UnicoCell Biomed Co Ltd TPE:6794
79 GF Score
Price NT$77.90
GF Value NT$65.13
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is UnicoCell Biomed Co Ending Cash Position?

UnicoCell Biomed Co TPE:6794 -0.38% 79 Ending Cash Position is NT$46.55 Mil as of Jun. 2026. GuruFocus rates TPE:6794 with a GF Score™ of 79/100 and a GF Value™ of NT$65.13 (Modestly Overvalued). The stock has 3 warning signs investors should review.

UnicoCell Biomed Co's Ending Cash Position for the quarter that ended in Jun. 2026 was NT$46.55 Mil.

UnicoCell Biomed Co's quarterly Ending Cash Position increased from Dec. 2025 (NT$40.84 Mil) to Mar. 2026 (NT$75.07 Mil) but then declined from Mar. 2026 (NT$75.07 Mil) to Jun. 2026 (NT$46.55 Mil).

UnicoCell Biomed Co's annual Ending Cash Position declined from Dec. 2023 (NT$19.90 Mil) to Dec. 2024 (NT$9.57 Mil) but then increased from Dec. 2024 (NT$9.57 Mil) to Dec. 2025 (NT$40.84 Mil).

UnicoCell Biomed Co Ending Cash Position Related Terms

UnicoCell Biomed Co Ending Cash Position Historical Data

* Premium members only.

The historical data trend for UnicoCell Biomed Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UnicoCell Biomed Co Ending Cash Position Chart

UnicoCell Biomed Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only 130.85 53.64 19.90 9.57 40.84

UnicoCell Biomed Co Quarterly Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.40 49.51 40.84 75.07 46.55
TPE:6794
79GF Score
UnicoCell Biomed Co Ltd TPE:6794
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UnicoCell Biomed Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

UnicoCell Biomed Co's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=9.571+31.269
=40.84

UnicoCell Biomed Co's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=75.066+-28.515
=46.55

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of NT$46.55 Mil mean?
UnicoCell Biomed Co (TPE:6794) has a Ending Cash Position of NT$46.55 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on UnicoCell Biomed Co and its competitors.
Is UnicoCell Biomed Co's Ending Cash Position too high?
UnicoCell Biomed Co's current Ending Cash Position is NT$46.55 Mil. Overall, UnicoCell Biomed Co has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UnicoCell Biomed Co's Ending Cash Position compare to VRTX and REGN?
UnicoCell Biomed Co's Ending Cash Position of NT$46.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on UnicoCell Biomed Co and its competitors. UnicoCell Biomed Co's current Ending Cash Position is NT$46.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UnicoCell Biomed Co stock overvalued right now?
Based on GuruFocus' analysis, UnicoCell Biomed Co (TPE:6794) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$65.13, compared to a current price of NT$77.90 — trading 19.6% above its estimated fair value. The current Ending Cash Position is NT$46.55 Mil. UnicoCell Biomed Co's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For UnicoCell Biomed Co (TPE:6794), the current Ending Cash Position is NT$46.55 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UnicoCell Biomed Co (TPE:6794) Overvalued in 2026?

Based on GuruFocus' analysis, UnicoCell Biomed Co stock appears to be overvalued. The current stock price of NT$77.90 is trading 19.6% above its estimated GF Value™ of NT$65.13. GuruFocus considers UnicoCell Biomed Co to be Modestly Overvalued.

Key valuation signals for TPE:6794:

  • Ending Cash Position: NT$46.55 Mil
  • GF Value™: NT$65.13 vs. price of NT$77.90 (19.6% above fair value)
  • GF Score™: 79/100 with 3 warning signs

No single metric tells the full story. See the TPE:6794 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UnicoCell Biomed Co Business Description

Address Minquan East Road, 5th Floor, No. 13-20, Section 6, Neihu District, Taipei, TWN, 11494
UnicoCell Biomed Co Ltd is engaged in new drug R&D and human tissue-derived stem cell inspection and testing, extraction, storage, and technology R&D. It focuses on researching and developing stem cells and its derived technology for medical applications, with the goal of advancing human health and improving quality of life. The company's products include Allogeneic Adipose Stem Cell Bank, Autologous Stem Cell Therapy, Conditioned Medium, Mass Production and CDMO, Cryogenic Vial (Class 2 Medical Device), and Testing services. It operates in single segment. Geographically, its operations are spread across Taiwan, Japan and Others with Taiwan generating the majority of the revenue.
79GF Score

Get the complete analysis for TPE:6794

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$77.90
Price
NT$65.13
GF Value